|10th September 2020||Henry A Mckinnell||5.853||Grant/award etc.||$286.39||$1,676.24|
|10th September 2020||Henry A Mckinnell||99||Grant/award etc.||$286.88||$28,401.12|
|3rd August 2020||(International) Ltd Vifor||31,823||Open or private sale||$53.62||$1,706,307.89|
|3rd August 2020||(International) Ltd Vifor||16,650||Open or private sale||$54.58||$908,806.95|
|3rd August 2020||(International) Ltd Vifor||785||Open or private sale||$52.92||$41,540.24|
|31st July 2020||(International) Ltd Vifor||10,009||Open or private sale||$51.74||$517,867.66|
|31st July 2020||(International) Ltd Vifor||29,699||Open or private sale||$52.57||$1,561,252.67|
|31st July 2020||(International) Ltd Vifor||694||Open or private sale||$54.33||$37,704.19|
|30th July 2020||(International) Ltd Vifor||1,156||Open or private sale||$53.37||$61,692.48|
|30th July 2020||(International) Ltd Vifor||24,458||Open or private sale||$54.43||$1,331,354.11|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 3/10.
ChemoCentryx, Inc. focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact.